Brilaroxazine

Drug identity checked against registry records

Also recorded as RP5063

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335Reviva PharmaceuticalsPhase 3Recruiting2025-02Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.